SYN-002 / Synergys Biotherap - LARVOL DELTA

Ex Vivo Targeting of the Latent Cytomegalovirus Reservoir in Human Kidneys to Prevent Virus Reactivation Post Transplantation (WTC 2025) - "Treatment for CMV during NMP appeared safe and reduced the foci of infection in cells isolated from the perfusate. The ex vivo data provide compelling proof-of-concept that SYN002 is highly efficacious and safe and that the use of SYN002 in this setting can be expected to provide clinical benefit. SYN002 constitutes a novel approach for the prevention of transplantation associated CMV reactivation and disease without the need for antiviral prophylaxis."

Late-breaking abstract • Post-transplantation • Preclinical • Cytomegalovirus Infection • Immunology • Infectious Disease • Solid Organ Transplantation • Transplant Rejection • Transplantation • FABP1 • IGFBP7 • TIMP2